CD8A and neoplasm: Next, to evaluate the role of secondary lymphoid organs in the differentiation of tumor-specific CD8+ T cells, we used FTY720 treatment to block sphingosine 1-phosphate receptor-1 and inhibit the migration of effector T cells from secondary lymphoid tissue (32, 33).